Zydus Lifesciences 과거 수익 실적
과거 기준 확인 5/6
Zydus Lifesciences은 연평균 21.4%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 13.3%였습니다. 매출은 연평균 8.2%의 비율로 증가했습니다. Zydus Lifesciences의 자기자본이익률은 18.3%이고 순이익률은 19.9%입니다.
주요 정보
21.4%
수익 성장률
21.8%
EPS 성장률
| Pharmaceuticals 산업 성장 | 17.5% |
| 매출 성장률 | 8.2% |
| 자기자본 수익률 | 18.3% |
| 순이익 | 19.9% |
| 최근 수익 업데이트 | 30 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price
Nov 15
Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching
Sep 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market
Aug 30Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 03Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jul 19Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 05Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jun 20Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Jun 10Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
May 25Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Dec 06With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case
Aug 23Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
Jul 17We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jun 24Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00
Jun 10Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
May 21Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15수익 및 비용 분석
수익 및 비용 분석
Zydus Lifesciences 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Sep 24 | 214,835 | 42,777 | 45,251 | 0 |
| 30 Jun 24 | 206,153 | 41,685 | 43,988 | 0 |
| 31 Mar 24 | 195,474 | 38,365 | 42,457 | 0 |
| 31 Dec 23 | 190,241 | 29,562 | 40,238 | 0 |
| 30 Sep 23 | 187,760 | 28,109 | 38,955 | 0 |
| 30 Jun 23 | 184,127 | 25,262 | 38,143 | 0 |
| 31 Mar 23 | 172,374 | 19,649 | 37,649 | 0 |
| 31 Dec 22 | 164,335 | 20,785 | 34,572 | 0 |
| 30 Sep 22 | 157,110 | 19,629 | 33,594 | 0 |
| 30 Jun 22 | 153,361 | 21,710 | 33,072 | 0 |
| 31 Mar 22 | 151,099 | 22,416 | 32,498 | 0 |
| 31 Dec 21 | 157,609 | 23,267 | 33,869 | 0 |
| 30 Sep 21 | 157,389 | 23,269 | 34,155 | 0 |
| 30 Jun 21 | 156,130 | 22,600 | 33,716 | 0 |
| 31 Mar 21 | 144,035 | 22,016 | 31,250 | 0 |
| 31 Dec 20 | 150,076 | 18,465 | 33,882 | 0 |
| 30 Sep 20 | 148,501 | 16,932 | 33,738 | 0 |
| 30 Jun 20 | 143,967 | 13,270 | 33,550 | 0 |
| 31 Mar 20 | 142,531 | 11,766 | 33,080 | 0 |
| 31 Dec 19 | 142,338 | 12,448 | 30,652 | 0 |
| 30 Sep 19 | 141,736 | 13,816 | 29,702 | 0 |
| 30 Jun 19 | 137,682 | 16,919 | 28,947 | 0 |
| 31 Mar 19 | 131,656 | 18,488 | 28,315 | 0 |
| 31 Dec 18 | 126,706 | 19,954 | 26,962 | 0 |
| 30 Sep 18 | 123,526 | 20,305 | 26,377 | 0 |
| 30 Jun 18 | 126,133 | 21,168 | 25,801 | 0 |
| 31 Mar 18 | 119,049 | 17,946 | 24,874 | 0 |
| 31 Dec 17 | 111,691 | 15,705 | 23,076 | 0 |
| 30 Sep 17 | 102,206 | 13,511 | 22,178 | 0 |
| 30 Jun 17 | 93,397 | 12,277 | 15,718 | 0 |
| 31 Mar 17 | 93,765 | 14,904 | 20,774 | 0 |
| 31 Dec 16 | 97,494 | 11,323 | 22,840 | 0 |
| 30 Sep 16 | 97,971 | 12,812 | 22,110 | 0 |
| 30 Jun 16 | 97,221 | 14,186 | 13,863 | 0 |
| 31 Mar 16 | 94,268 | 19,339 | 19,875 | 0 |
| 31 Dec 15 | 95,901 | 14,843 | 26,749 | 0 |
| 30 Sep 15 | 92,453 | 13,766 | 26,744 | 0 |
| 30 Jun 15 | 89,795 | 12,638 | 26,277 | 0 |
| 31 Mar 15 | 86,513 | 11,506 | 19,060 | 0 |
| 31 Dec 14 | 82,955 | 10,394 | 24,740 | 0 |
| 30 Sep 14 | 79,777 | 9,435 | 24,184 | 0 |
| 30 Jun 14 | 76,165 | 8,488 | 24,041 | 0 |
| 31 Mar 14 | 72,034 | 8,036 | 23,771 | 0 |
| 31 Dec 13 | 68,204 | 8,266 | 21,595 | 0 |
양질의 수익: ZYDUSLIFE 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: ZYDUSLIFE 의 현재 순이익 이익률 (19.9%) 작년보다 높습니다 (15%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: ZYDUSLIFE 의 수익은 지난 5년 동안 매년 21.4% 씩 크게 증가했습니다.
성장 가속화: 지난 1년간 ZYDUSLIFE 의 수익 증가율( 52.2% )은 연간 평균( 21.4% 초과합니다. ).
수익 대 산업: 지난 1년간 ZYDUSLIFE 수익 증가율( 52.2% )은 Pharmaceuticals 업계 20.5% 초과했습니다.
자기자본 수익률
높은 ROE: ZYDUSLIFE 의 자본 수익률( 18.3% )은 낮음으로 간주됩니다.